Vanessa Tassell
Mirati Therapeutics (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Gastrointestinal Tumor Research and Treatment, Gastric Cancer Management and Outcomes, Liver physiology and pathology, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer(2013)3,387 cited
- → Institutional implementation of clinical tumor profiling on an unselected cancer population(2016)444 cited
- → Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure(2009)366 cited
- → Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.(2011)174 cited
- → Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer(2013)149 cited
- → Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models(2017)147 cited
- → Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure(2012)136 cited
- → Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).(2010)68 cited
- → Complex renal cysts associated with crizotinib treatment(2015)61 cited
- → Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)(2012)57 cited